Coagulation

New VOYAGER PAD Analyses Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin Across High-Risk and Complex Patient Populations with Peripheral Artery Disease (PAD)

Retrieved on: 
Tuesday, November 14, 2023
ICH, Rivaroxaban, Buerger's test, Research, Safety, Johnson & Johnson, Thrombin, Food, PAD, DPI, American Heart Association, AHA, Risk, Amputation, CAD, Patient, ALI, Myocardial infarction, Intracerebral hemorrhage, Coagulation, LER, TIMI, FDA, Medical Affairs Bureau, Division, Janssen Pharmaceuticals, Comorbidity, MACE, Vascular disease, Stroke, Standard of care, University, Bleeding, Aspirin, EGFR, Janssen, Disability, Anschutz Medical Campus, Metabolism, Pharmaceutical industry

TITUSVILLE, N.J., Nov. 14, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of XARELTO® (rivaroxaban [2.5 mg twice daily plus aspirin 100 mg once daily]) over standard of care (aspirin alone). Data from the two analyses demonstrate the role of XARELTO® in treating both high-risk and fragile patients and those with and without comorbid coronary artery diseases (CAD). Results were presented at the American Heart Association's (AHA) 2023 Scientific Sessions, hosted in Philadelphia, Pennsylvania, November 11-13, 2023.

Key Points: 
  • "These analyses reinforce the consistency of the favorable benefit-risk profile of XARELTO® plus aspirin for patients with vascular disease, regardless of comorbidity.
  • In fragile patients treated with XARELTO® plus aspirin, 6.2% of patients experienced a MALE compared to 10.3% of patients treated with placebo.
  • In patients with PAD only, 11% of patients treated with XARELTO® plus aspirin experienced a MACE versus 9.8% of patients treated with placebo.
  • Overall, the safety of XARELTO® plus aspirin in patients with PAD was consistent regardless of CAD with no significant interactions.

Venus Concept Launches Venus Versa Pro, its new multi-application platform for face and body treatments

Retrieved on: 
Wednesday, November 1, 2023
Venus, Acne, EVP, Growth, IPL, Annual report, Patient, Marketing, Communication, Coagulation, Music

TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the commercial launch of its new multi-application platform Venus Versa Pro in the United States.

Key Points: 
  • TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today the commercial launch of its new multi-application platform Venus Versa Pro in the United States.
  • “Venus Versa Pro is our first platform product to launch following our recently announced Venus Aesthetic Intelligence (“Venus AI”) rebrand.
  • "Venus Versa has been one of the company’s best-selling products over the last 5 years with thousands of installations worldwide.
  • We are confident that this next-generation Venus Versa Pro can build on the success of Venus Versa and be an important contributor to our revenue growth in 2024 and beyond."

Incheon National University Scientists Develop New Hydrogels for Wound Management

Retrieved on: 
Monday, November 6, 2023
DA, Polymerization, Engineering, Water, Catecholamine, Associate, Hyperoxia, Life, Human, Oxygen, Dopamine, Anesthetic, Coagulation, Wound healing, Research, Cell proliferation, Gel, KPA, Regeneration, Accident, Calcium peroxide, Gas, Incheon National University, GOTS, Toxicity, Suture, Infection, Hydrophobic light-activated adhesive, Adhesive, Silk

GWANGJU, South Korea, Nov. 6, 2023 /PRNewswire/ -- Wound management is essential to ensure a speedy and safe recovery, and tissue adhesive patches are an attractive option that can replace sutures and stapling. In a recent study, researchers from Korea developed a new type of gelatin-based tissue adhesive hydrogel that locally generates oxygen through a reaction mediated by calcium peroxide, which improves the adhesiveness of the material and greatly enhances the healing process.

Key Points: 
  • Open wounds, whether caused by accidents or from medical procedures like surgery, require proper management to speed up healing and prevent infections.
  • While sutures and staples are common wound closure methods, they can cause secondary tissue injuries, potentially leaking fluids and gases and requiring anesthetics.
  • Against this backdrop, a team of researchers from Korea, led by Associate Professor Kyung Min Park of Incheon National University set out to find an effective solution to these limitations.
  • The research team has high hopes for the potential of the GOTs to become a cost-effective solution for wound management in a clinical setting.

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

Retrieved on: 
Tuesday, October 31, 2023
Other Health, Research, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Science, Surgery, Biotechnology, FDA, Other Science, Health, Post-traumatic stress disorder, Rat, Analgesic, Nanotechnology, National Center for Advancing Translational Sciences, IND, Central nervous system disease, Food, NCATS, Chronic pain, Hematology, Mortality, Morphine, US Food Sovereignty Alliance, CNS, Nanoparticle, Administration, Human, Traffic barrier, Transitive dependency, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Completeness, DRF, Thermoregulation, Animal, Brain, NIH, CFA, Pain management, Drug tolerance, Dog, Pain, MET, Hypersensitivity, Bangladesh Technical Education Board, Coagulation, Central nervous system, Pharmaceutical industry

Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.

Key Points: 
  • Envelta utilizes a novel and patented intranasal drug delivery system, Molecular Envelope Technology (MET) to bypass the blood-brain barrier.
  • The MET was developed by Nanomerics, Ltd. , a UK-based nanotechnology research and development company that has licensed its MET-LENK to Virpax.
  • The nose-to-brain MET platform protects molecules from biodegrading and enhances the bioavailability of product candidates on its transport to the brain.
  • “We are grateful to the FDA for the thorough and clear direction that was provided to us in our pre-IND meeting.

Global Rare Hemophilia Factors (I, II, VII) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Health, Genetics, FDA, Child, Plasma, Second Continental Congress, Orphan Drug Act of 1983, Health care, Haemophilia, ODA, Hand, Treatment, Congress, Prevalence, VII, Coagulation factor VII, Personal protective equipment, Coagulation, Infection, Quality of life, Growth, COVID-19, Factor VII deficiency, Patient, Diagnosis, Speciality chemicals, Pharmaceutical industry, Tisagenlecleucel, Safety, Cryoprecipitate

The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Hemophilia Factors Market Size, Share & Trends Analysis Report By Type (Factor I, Factor II, Factor VII), By Treatment (Factor Concentrates, Fresh Frozen Plasma, Cryoprecipitate), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare hemophilia factors market is poised for substantial growth, targeting a USD 499.5 million market size by 2030, accompanied by a noteworthy compound annual growth rate (CAGR) of 6.9% from 2023 to 2030.
  • Prophylactic treatment is recommended for individuals with severe rare hemophilia factor disorders to prevent bleeding episodes and enhance their quality of life.
  • This intensified focus on patient safety measures is expected to have enduring benefits for rare hemophilia factor administration.

eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys

Retrieved on: 
Wednesday, October 11, 2023
Xenotransplantation, Engineering, Biomarker, Hope, Inflammation, Genome, Endothelium, Risk, Data, Massachusetts General Hospital, Survival, Coagulation, Transplant, Hospital, Patient, Organ dysfunction, Pelvic floor dysfunction, Gene, Harvard Medical School, Transgene, NHP, Human, Filtration, Vaccine, Dentistry, Nature

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development.

Key Points: 
  • These results represent the largest and most comprehensive preclinical dataset published in the field to date.
  • Recipient survival in the preclinical setting has historically been measured in weeks or months.
  • The publication titled: “ Design and Testing of a Humanized Porcine Donor for Xenotransplantation ,” reported long-term survival of NHP recipients of the company’s genetically engineered porcine kidneys.
  • “At eGenesis, we are focused on transformational progress for the field – improving long-term survival for transplant recipients from months to years,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.

VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility

Retrieved on: 
Thursday, October 12, 2023
Health, Surgery, Research, Pharmaceutical, Science, Biotechnology, United, Moyamoya disease, Pathology, Regenerative medicine, Clinical trial, Duke University Hospital, Dialysis, Coagulation, Management, Pharmaceutical industry

This marks a pivotal strategic moment for the Company as it broadens its international focus.

Key Points: 
  • This marks a pivotal strategic moment for the Company as it broadens its international focus.
  • Dr. Lawson, a distinguished scientist and vascular surgeon, brings over two decades of experience in developing vascular technologies.
  • Dr. Lawson also co-founded InnAVasc, a vascular device company dedicated to safe and reliable vascular access for hemodialysis which was acquired by Gore.
  • Dr. Jeffrey Lawson, CEO of VarmX, said: "I have been very impressed with VarmX’s achievements since I joined in March and I’m grateful for the opportunity to lead the Company into this new chapter.

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023
Control, Integra, Partnership, Acquisition, DACH, Bleeding, Risk, Animal, DRE, Coagulation, Olympus Corporation, Integra LifeSciences, Blood, Trauma, Anesthesia, Scar, Infection, Antibody-drug conjugate, Veterinarian, Tissue, Electrosurgery, Veterinary medicine, Symmetry, Medical device, Birth control, Dentistry, Medtronic

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.

Veterinary Electrosurgery Market worth $120 million | MarketsandMarkets

Retrieved on: 
Tuesday, October 10, 2023
Control, Integra, Partnership, Acquisition, DACH, Bleeding, Risk, Animal, DRE, Coagulation, Olympus Corporation, Integra LifeSciences, Blood, Trauma, Anesthesia, Scar, Infection, Antibody-drug conjugate, Veterinarian, Tissue, Electrosurgery, Veterinary medicine, Symmetry, Medical device, Birth control, Dentistry, Medtronic

In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).

Key Points: 
  • In April 2021, DRE Veterinary (US) partnered with Avante Health Solutions (US).
  • Minimally Invasive: Electrosurgery is often minimally invasive, resulting in smaller incisions, less pain, and reduced scarring for animals post-surgery.
  • Versatility: Electrosurgical instruments can be adapted for various veterinary procedures, including soft tissue surgeries, dermatological treatments, and ophthalmic surgeries, making them versatile tools in veterinary medicine.
  • Enhanced Patient Outcomes: Overall, the advantages of electrosurgery contribute to improved patient outcomes, making it a valuable tool for modern veterinary practices and promoting the well-being of animals.

HemoSonics Wins Medical Device Network Excellence Award in Two Categories

Retrieved on: 
Thursday, October 5, 2023
Hospital, Food, AUC, Business, Intelligence, Journal of Cardiothoracic Surgery, Intensive care medicine, Health, Coagulation, Artificial intelligence, FDA, New product development, Trauma, Cartridge, GlobalData, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Operating, Medical device

DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics, a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards. HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes. Clinicians don't need to wait on test results during a serious life-threatening bleeding event, and, as a result, patients receive optimized interventions as quickly as possible and only when needed.

Key Points: 
  • DURHAM, N.C., Oct. 5, 2023 /PRNewswire/ -- HemoSonics , a medical device company delivering individualized diagnostic solutions for acute care bleeding and the management of coagulation, announced today that the company has won in both the Product Launch and Business Expansion categories in the 2023 Medical Device Network Excellence Awards .
  • HemoSonics' Quantra Hemostasis System provides comprehensive whole-blood coagulation analysis at the point of care in less than 15 minutes.
  • The Medical Device Network Excellence Awards is an independent recognition program powered by the business intelligence of GlobalData .
  • HemoSonics also received an innovative technology contract award from Vizient, opening the door for the System to be adopted by hospitals and academic medical centers across the United States.